Search this site
3150 results found with an empty search
- Táche launches first chocolate pistachio milk with limited-edition Peppermint Mocha Barista
Plant-based milk brand Táche has expanded its pistachio beverage portfolio with the launch of Peppermint Mocha Barista, its first-ever chocolate pistachio milk. The limited-edition product combines chocolate and peppermint with the brand's signature creamy pistachio milk, marking the latest innovation from the company as it looks to broaden the applications of pistachios within the plant-based beverage category. Developed over more than two years, the new product is made with real premium pistachios and is free from seed oils and fillers. It is also entirely plant-based and non-GMO. Designed for both at-home and foodservice use, Peppermint Mocha Barista can be consumed straight from the carton or used in a variety of applications, including coffee, hot chocolate, cocktails and seasonal baking. Roxana Saidi, Founder and CEO of Táche, said the launch reflected the brand's ambition to explore the wider potential of pistachios in food and beverage. “When I started Táche, pistachio was still largely associated with snacking or artificially flavoured ice cream. I always believed this extraordinary ingredient deserved a much bigger place in food and beverage culture,” she said. “Peppermint Mocha is an extension of that belief, and we're just getting started.” Peppermint Mocha Barista joins an expanding portfolio that includes Táche's Barista and Classic Milk ranges, ready-to-drink Pistachio Milk Lattes and its recently launched Three-Ingredient Pistachio Milk. Following the introduction of Pumpkin Spice Barista earlier this year, the new flavour represents the brand's second limited-edition seasonal release. Founded in 2020, Táche has positioned itself as a specialist in pistachio-based plant milks, targeting both professional baristas and consumers looking for alternatives to traditional dairy and other plant-based beverages. Táche Peppermint Mocha Barista is available through the brand's website and Thrive Market, with a recommended price of $9 per 32 fl oz carton for direct-to-consumer purchases and $7.99 per carton at retail.
- Start-up spotlight: NuCicer
In this instalment of 'Start-up spotlight,' we speak to NuCicer, a US-based food-tech company developing nutrition-boosted chickpeas using advanced genomic modelling, speed breeding and AI-led technologies. Kathryn Cook, the company's CEO and co-founder, tells us more about the mission behind NuCicer's work, and the benefits of its recently launched 'Nuchi' high-protein chickpeas. Kathryn Cook What led to NuCicer's establishment, and what is the company's mission? NuCicer began by asking why we take starch-rich crops built for the industrial era, then rely on heavy processing, additives and masking agents to make up for their limits. My father, Douglas Cook, had spent decades at UC Davis studying chickpeas and their wild ancestors. In that research, he uncovered how much genetic diversity centuries of domestication had left behind. As an engineer by training, I saw an opportunity hiding in that data. We founded NuCicer in 2019 to start where nutrition, flavour and functionality begin, which is in the seed. Our mission is to close the gap between what nature already made and what the world needs, faster than anyone thought possible. Why did you choose to focus on chickpeas? Chickpeas are a humble, underrated crop. They are naturally rich in protein and fibre, relatively mild in flavour, and as a legume they naturally replenish the soil with their own nitrogen. But most chickpeas were bred for canning and hummus, not for ingredients. We've been eating the white bread of chickpeas. Their wild relatives hold far more diversity, including traits that were never optimised, so there was a great deal of potential left to bring back. Chickpeas gave us a clear place to prove that better food starts with better crops. Can you tell us about the key technologies that enable you to develop your high-protein chickpea variant, and how these technologies work? Three things work together. First, a genetic library with 40 times the diversity of commercial chickpea, built by crossing modern varieties with wild and heirloom relatives through manual cross-pollination, not gene editing or genetic modification. Second, predictive genomic modeling that allows us to address highly complex traits and scores possible crosses against the combined trait package we want, such as protein-to-fat ratio, flavour and processability, before we even make the cross. Third, controlled-environment speed breeding that runs more than five generations a year, backed by rapid lab measurements of nutritional composition, function and flavour. Together they compress more than a decade of breeding into under four years. How is the use of AI helping to enhance and accelerate plant breeding techniques? AI helps us decide what to cross. Our models learn from every cycle of genetic and performance data, so they predict which crosses are most likely to deliver the traits we want, and we avoid spending seasons and resources on the rest. Each generation then adds data that makes the next round of predictions better, so the advantage compounds. That is how we compress development from about ten years to under four. The breeding itself stays natural, with manual cross-pollination, guided by better information. Beyond higher protein content, what are some of the other benefits of NuCicer's chickpeas? Nuchi has 50% more protein and 25% less fat than conventional chickpeas, with a strong fibre profile, so protein and fibre arrive together. It comes in multiple formats, so manufacturers can choose what fits their product: a high-protein flour, a pre-gelatinised high-protein flour, a low-fat flour and a protein concentrate. Its flavour is mild and naturally neutral, so there is less to mask and fewer additives, and it works with existing pea protein manufacturing infrastructure without the need for solvent extraction. In the field, it matures two to three weeks earlier than standard commodity chickpea and reduces the need for desiccants. And as a legume, it fixes nitrogen, helping reduce reliance on synthetic fertiliser. How have you found the industry response to Nuchi so far, since the launch earlier this year? The response has been excellent. Manufacturers in snacks, bakery and pasta have been among the quickest to engage with strong consumer pressure to improve nutrient-density in the ‘carb aisle’ while balancing clean-label demand. They appreciate a food ingredient that has been developed specifically for the needs of manufacturers and mindful of the surging market demand for protein and fibre packed into a single ingredient. We also receive positive feedback on the neutral flavour and on how well Nuchi fits the ingredient manufacturing infrastructure they already run. How is NuCicer working collaboratively with other companies in the food and beverage manufacturing sector? Collaboration is built into how we work, because a better crop only matters once it reaches the table. We partner with growers and grain merchandisers for production and processing, and with ingredient processors and food manufacturers to test Nuchi in real products. We work with university partners and research institutions, including but not limited to UC Davis, University of Manitoba and NIZO, on a variety of scientific exploration and trialing. We also provide technical support to formulators testing our products across food applications. You announced a partnership with Stricks Ag in March. How has this partnership developed since, and do you plan to continue this into 2027? The partnership between NuCicer and Stricks Ag began in March to deploy high-protein chickpeas across 10,000 acres in the summer of 2026 to meet growing market demand. Stricks Ag led production and primary processing through its grower network and facilities, with planting in late spring and harvest in late summer. As we continue to scale the variety, we are pleased by the results and, as with any product, continue to learn how to maximise both yield and protein – for example, with early season planting and by taking advantage of its shorter growing season to harvest before fall rains begin. It has been a strong foundation, and we’ll be building on our total acreage with an expanded grower network in 2027. What key food industry challenges does NuCicer hope to address with its solutions? Food producers are stuck choosing among protein, fibre, flavour, economics and a clean label. Hitting nutritional targets often means heavy processing and added ingredients to cover off-flavours, while keeping the label short can impair taste, texture or scale. And as eating habits shift and demand for protein and fibre increases, every bite has to do more nutritionally. Because the industry relies on starch-rich commodity crops, processors spend enormous effort fixing downstream what the crop lacks. By starting in the crop, we can deliver protein, fiber and flavour in the ingredient itself, with less processing and fewer additives. What has been your biggest achievement to date? The three achievements our team is most proud of are moving from innovation to scale, taking a high-protein chickpea from research to more than 10,000 acres planted in 2026, and the successful commercial launch of Nuchi to food manufacturers. I would add that NuCicer receiving two international recognitions, by being named a 2026 Etiko 250 SDG Changemaker, and part of the Norrsken100, have been a welcome testament to our full team and the investors who have believed in us from the start. What's next for NuCicer? Any big plans you can share? Nuchi is the first proof, but not the last. Our platform compounds, with each generation building on the last, so we expect the next generations of Nuchi to bring even more benefit to manufacturers and growers. Over time, the same approach can be applied to other crops. In the near term, our focus is scaling supply for 2027 and working alongside more manufacturers as they bring Nuchi into their products. But expect to hear more from us as we grow and get traction. If you could offer one piece of advice to aspiring start-ups in the food and beverage industry, what would it be? Go back to where the problem starts. If your solution keeps compensating for the same upstream limitation, it may be worth asking whether the fix belongs earlier in the chain. For us, that meant going back to the seed. We also believe in partnering for scale, which means building on existing infrastructure and partners, so you can grow without building everything yourself.
- 21st.Bio files EU Novel Food application for precision-fermented beta-lactoglobulin
Danish biotech start-up 21st.Bio has filed a European Union (EU) Novel Food application for its bovine beta-lactoglobulin (BLG), a milk protein that the company produces without animal input using precision fermentation technology. The filing follows regulatory approval for sales in the US, obtained in October 2025, with the company now offering the same technology to the European market. Once approved, 21st.Bio said its solution will support resource-efficient dairy protein production and sale in Europe amid ongoing supply constraints impacting the whey protein market. BLG is the predominant protein in whey protein from milk, valued for its high-quality amino acid profile and versatility. Precision fermentation involves ‘training’ microorganisms to produce specific targeted ingredients, such as high-value proteins, in bioreactors. It can be used to produce a wide range of traditionally animal-derived ingredients, independent of animal agriculture. 21st.Bio’s BLG Essential+ solution is produced using Aspergillus oryzae, a microorganism used for centuries in traditional Japanese food fermentation, including soy sauce and miso. The production platform has been developed and refined by fellow biotech specialist Novonesis, and has been licenced and further advanced by 21st.Bio for efficient alt-protein production at scale. A 2025 peer-reviewed study in Applied Microbiology and Biotechnology described the strain lineage as the first mycotoxin-free A. oryzae lineage for industrial production of alternative and novel proteins. José Arnau, chief of strain engineering and regulatory affairs at 21st.Bio and co-author of the study, said: “This is a well-characterised production platform with consumer safety designed into the strain”. “Advanced genome analyses allow regulators to assess safety at strain level with far greater precision, and for proven platforms producing proteins that match those found in nature, the regulatory requirements should be lower and the safety evaluation more straightforward... and faster.” While Europe has a strong precision fermentation and alternative protein ecosystem, 21st.Bio noted that preparing a full EU dossier required ‘years of scientific and procedural work,’ with subsequent approval processes and timelines making it difficult for companies to plan investments, facilities and launch products in the region. The company is calling for a fast-track pathway for ‘well-characterised, nature-identical’ food proteins produced using host strains and technologies with demonstrated records of safe use. This, it believes, will preserve Europe’s high safety standards while giving applicants a clearer timetable. Thomas G Schmidt, co-founder and CEO of 21st.Bio, said: “Europe has the science, the companies and the industrial heritage in precision fermentation to lead the wave of healthy and nutritious food production”. “What Europe still needs is a home market that allows industrially proven technology to move from laboratories into fermentation factories built in Europe. A predictable, science-based route to market can strengthen food resilience, attract industrial investment and ensure that European innovation is commercialised in Europe.” Top image: © 21st.Bio
- New Culture receives ‘world-first’ approval from CDFA to produce animal-free dairy mozzarella
US-based precision fermentation dairy company New Culture has received the necessary approvals from the California Department of Food and Agriculture (CDFA) to produce its animal-free dairy mozzarella. The permit is claimed to be the first of its kind for mozzarella containing real dairy proteins made in an animal-free precision fermentation process. New Culture will manufacture the alt-dairy cheese in its CDFA-approved production facility in the San Francisco Bay Area. According to New Culture, CDFA’s review included an evaluation of the safety and controls of its manufacturing process, as well as the sustainably of the site and the product label. The review also resulted in CDFA approval of an official product name, ‘Mozzarella Style Animal-Free Dairy Cheese’. To make the cheese, New Culture uses its animal-free alpha-S1-casein protein, made from fermenting sugars. The ingredient is also free from lactose, cholesterol and trace hormones and antibiotics, the company said, representing an estimated 85% reduction in greenhouse gas emissions and 95% reduction in land and water use compared with conventional cow’s milk-derived casein. Inja Radman, New Culture co-founder and CSO, said: “The team at New Culture is fundamentally reshaping the dairy industry. Thanks to CDFA’s rigorous and collaborative approach, we now have the necessary product manufacturing, facility and label approvals for our animal-free dairy mozzarella.” “While there remains work ahead, the most important part of these approvals is that this pushes us one massive step closer to commercialisation.” The company is now turning its sights to the sale of its product, including efforts to further scale commercial manufacture of the casein and cheese. In July 2026, New Culture secured its second US patent covering cheese made with animal-free casein. The most recent patent focuses specifically on mozzarella made using its proprietary ingredient, while an earlier patent granted in 2023 provides wider protection for cheese products made using recombinant alpha casein across multiple cheese types. The company is preparing for an initial launch through the foodservice channel, targeting pizzerias first. In 2023, it piloted the launch of its animal-free mozzarella through a partnership with chef Nancy Silverton at the Los Angeles restaurant, Pizzeria Mozza. A wider roll-out was expected to begin in 2024, but was delayed, with New Culture subsequently navigating regulatory processes concerning product labelling. The CDFA approval brings it closer to these commercialisation goals, after the company achieved US Generally Recognized as Safe (GRAS) status for the ingredient in 2024.
- Emsland introduces Empure EF 1000 pea flake ingredient solution
German ingredients manufacturer Emsland has introduced Empure EF 1000, an ingredient made from whole yellow peas and designed to help manufacturers boost protein and fibre content. The pea flake ingredient is well-suited to snacks and bakery products, designed to offer both appealing sensory properties and straightforward processing. It is a thermally treated pea flake bringing the nutritional profile of whole yellow peas into a convenient format, providing approximately 23% protein and 15% fibre on a dry matter basis. © Emsland Group Emsland said the solution can deliver a ‘versatile building block’ for more nutrient-dense food products, with consumers increasingly seeking snacks that offer more nutritional value while remaining enjoyable and affordable. According to the company, in a baked snack formulation, the ingredient achieved almost three times more protein and twice the fibre content compared with the original formulation, qualifying for ‘high-protein’ and ‘high-fibre’ nutrition claims – while retaining the potato chip’s crisp texture, colour and taste. Andre Heilemann, R&D director at the Emsland Group, said: “Healthy snacks have moved from niche to mainstream. Empure EF 1000 gives our customers greater flexibility when developing products with higher protein and fibre content.”
- Amyris to acquire sweet protein producer Oobli
Biomanufacturing company Amyris has announced it will acquire Oobli, a fellow US-based food-tech company that produces fermentation-derived sweet protein ingredients. The acquisition will bring together Amyris’ scientific and manufacturing capabilities with Oobli’s protein fermentation expertise. Both companies are headquartered in California, with complementary activities in the biotech space. Amyris creates speciality molecules for a range of industries, including food flavours and fragrances, beauty and personal care, and more. Founded in 2003, it uses advanced fermentation technology to create customised ingredients that aim to boost product performance. Meanwhile, Oobli uses its proprietary technology platform to create non-GMO sweet proteins that can help F&B companies significantly reduce sugar without sacrificing taste. Sweet proteins are originally found in fruits and berries near the equator, and are digested as protein, but taste like sugar. They bind directly to sweet taste receptors and are metabolised by the body as protein, delivering sweetness without gut disruption or blood sugar spikes. The proteins’ intense sweetness – generally hundreds to thousands of times sweeter than sugar, depending on the variety – means they can be used in food and beverage formulations in very small quantities, helping contribute to the industry’s wider sugar reduction goals in line with efforts to improve public health. Kathy Fortmann, CEO of Amyris, said: “Oobli is poised to transform how sweetness makes it to market, and we are thrilled to bring our commercial scale and resources to further accelerate the sweet revolution”. “Further, by bringing Oobli's protein expertise together with our strain engineering, manufacturing scale and commercial capabilities, we see the potential to broaden our capabilities in food and beverage, personal care, flavour and fragrances, agriculture and beyond, expanding the ways we can help customers innovate.” Oobli’s portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit sweet proteins (scientifically known as brazzein, monellin and thaumatin, respectively). The solutions have achieved US Food and Drug Administration Generally Recognized as Safe (GRAS) status, GRAS-affirmed for use as a natural flavour across different applications including sports nutrition, dairy, beverages, chocolate and confectionery, and bakery. The acquisition follows Amyris’ manufacturing capacity expansion earlier this year at its advanced fermentation facility in Barra Bonita, Brazil. The latest move marks the company’s continued technology and commercial expansion, growing Amyris’ presence in the protein- and peptide-based solution space. The acquisition, the financial terms of which were not disclosed, is expected to close in the coming weeks. Amyris said that all existing customer commitments and brand partnerships will continue to be honoured uninterrupted. Ali Wing, CEO of Oobli, said: “It Oobli, we have always believed there was a better way to deliver the sweet taste consumers love, without the trade-offs to health and our environment. It is with immense pride that we look back on the breakthroughs we have achieved.” “Joining forces with Amyris gives us the scale and resources to realise our ambition of making sweet proteins the global standard in sweetness solutions. Sweet proteins are an idea whose time is now.”
- Sambazon announces deal to buy fellow ‘superfruit’ brand Pitaya Foods
Açaí brand Sambazon has acquired fellow US ‘superfruit’ company Pitaya Foods, expanding its leading presence in the global organic frozen fruit category. The acquisition, the financial terms of which were not disclosed, expands Sambazon’s retail distribution by 20%, now reaching nearly 70% of US grocery stores. With Pitaya under its ownership, the company said it expects to reach 45% annualised revenue growth over the next 12 months. Sambazon, headquartered in California, was founded in 2000. It works directly with harvesting communities and operates processing facilities in the Amazon to bring wild-harvested açaí to retail and foodservice partners. It has now become the leading açaí brand in the US and the top exporter of açaí from Brazil, with a global presence spanning countries in the Americas, Europe, Asia-Pacific and the Middle East. Pitaya Foods is also headquartered in California and was founded in 2009. It specialises in organic dragon fruit, offering a wide-ranging portfolio of organic frozen ‘super fruits’ and smoothie products. Sambazon said its relationships with Amazon harvesting communities and sourcing infrastructure complement Pitaya Foods’ tropical fruit portfolio, with the two companies set to form a broader tropical superfruits platform serving international partners, with regenerative sourcing as a long-term focus. Aligning with this, Sambazon has also announced its achievement of an official Regenerative Organic certification, recognising its collaboration with family harvesters and commitment to environmental and social standards across sourcing and processing. Its sourcing approach focuses on soil and forest health and fair livelihoods for harvesting communities. Pitaya shares the commitment, having launched the first Regenified-certified organic frozen fruit line nationally at Whole Foods Market in 2025. It has close partnerships with family farms in Chile and Peru, helping advance regenerative practices that focus on soil health, biodiversity and community support. Ryan Black, co-founder and CEO of Sambazon, said: “We spent 26 years building a business around açaí and the belief that commercial success, care for people and protection of the places we source from are linked together”. “Bringing Sambazon and Pitaya Foods together gives that mission more reach, across more fruit, more formats and more partners,” he added, noting that açaí remains “the core of our business,” while the partnership advances its long-term vision for superfruits. Top image: © Toasted Pictures/Shutterstock.com
- Danone completes acquisition of Cocobella owner Made Group
Danone has completed its acquisition of Made Group, an Australia-based food and beverage company with a portfolio spanning high-protein ready-to-drink products, gut-health yogurts and coconut-based products. Made Group has an established presence in Australia, New Zealand and Southeast Asia, where it has recorded consistent double-digit growth and developed a track record in product innovation and marketing. Among its portfolio of brands is Cocobella, a plant-based brand offering a range of coconut products including coconut water and coconut yogurts. The business generated sales of more than €300 million for the financial year ending June 2026. Danone said Made Group would become a meaningful contributor to its Essential Dairy and Plant-Based (EDP) business in Asia Pacific. The acquisition, which was first announced in June, brings Made Group's health-focused brands and regional distribution capabilities into Danone's portfolio, strengthening its position in categories including high-protein, gut health and plant-based products. Antoine de Saint-Affrique, CEO of Danone, said: “Today, we are pleased to officially welcome Made to the Danone family. Made is a natural fit for Danone, with a portfolio of strong brands across high-protein, gut health and plant-based products." "They have built an impressive track record of innovation, strong consumer engagement and sustained growth across Australia, New Zealand and Southeast Asia. By combining Made's entrepreneurial culture, marketing expertise and proven route to market with Danone’s scale, science and category expertise, we are excited to unlock new opportunities, and reach even more consumers across Asia Pacific.” Amanda Butler, CEO of Made Group, “Our mantra of ‘making healthy happy’ is closely aligned with Danone’s mission to bring health through food to as many people as possible. Building on the growth and momentum we have achieved over the past few years, and with a shared commitment to health and a passion for innovation, we are excited to begin this new chapter alongside Danone." "By combining our complementary strengths, we are creating a stronger platform for growth in some of the most dynamic health and wellness categories across Asia Pacific, unlocking new opportunities for our brands, our people and the consumers we serve.” Top image: © Made
- Lantmännen to unveil new NordPea premium pea protein isolate at Fi Europe
Swedish agri-food cooperative Lantmännen has announced the launch of NordPea, a premium pea protein isolate developed through a joint initiative with US-headquartered Ingredion. NordPea will be produced at Lantmännen’s new €100 million plant protein facility in Lidköping, southwest Sweden. The site will have the capacity to process approximately 40,000 tonnes of peas and faba beans annually. NordPea is suitable for use across various plant-based food applications, including dairy analogues. The solution aims to meet growing demand for sustainable, high-quality plant proteins as interest in protein-enriched food and beverage products continues to grow. The ingredient will be produced in a vertical supply chain, from peas grown by Lantmännen’s cooperative farmers in Sweden. It will be officially launched at Food Ingredients Europe 2026 trade show in Frankfurt, Germany, next week. Fredrik Krook, managing director for biorefineries at Lantmännen, said: “We look forward to introducing NordPea to visitors at Food Ingredients Europe”. “Pea protein is an increasingly popular choice for food and beverage manufacturers In Europe, and NordPea will help to satisfy this growing demand with a high-quality ingredient produced in a sustainable manner.” Image credit: © Lantmännen
- Bio&Me teams up with Pip & Nut on new peanut butter granola
Gut health brand Bio&Me has teamed up with fellow UK food brand Pip & Nut in the launch of a new, high-fibre, high-protein granola made with Pip & Nut’s peanut butter. The product offers a crunchy, vegan-friendly granola containing a diverse blend of plant-based foods. These include wholegrain oats, dates, linseeds, sunflower seeds, carrot, chicory root, quinoa, extra virgin olive oil and peanuts. Each serving of the granola delivers 9g of fibre and 13g of protein. The new breakfast offering also remains true to both brands’ commitments to using only natural, plant-based ingredients, and contains no palm oil, emulsifiers or added sugars. Megan Rossi, co-founder of Bio&Me and known in the industry as ‘The Gut Health Doctor,’ has highlighted her PhD research showing fibre helps balance protein fermentation in the gut, supporting a healthier microbiome. She commented: “This launch, as with our other Fibre+Protein products, brings the protein:fibre index into the spotlight, something I studied during my PhD as a predictor of health outcomes, rather than focusing on individual nutrients in isolation”. “When it comes to gut health, variety really is the spice of life. Peanuts are a great example of a naturally nutritious whole food, providing protein, fibre and a range of other valuable nutrients. They count towards what I call the Super Six: vegetables, fruit, wholegrains, legumes, nuts and seeds, and herbs and spices. These are the six plant food groups I encourage everyone to include in their everyday diet.” Bio&Me x Pip & Nut Peanut Butter Granola launches on 16 November 2026, exclusively across 803 Tesco stores in the UK and priced at an RRP of £3.95 per 310g pack.
- Solar Foods receives positive EFSA scientific opinion for novel air protein ingredient
Finnish food-tech Solar Foods has received a positive scientific opinion from the European Food Safety Authority (EFSA), stating that its novel ‘air protein’ ingredient Solein is safe under the proposed conditions of use. The company is celebrating what it describes as a groundbreaking milestone on its route to commercialisation in the European Union (EU), becoming the world’s first company to receive a positive EFSA opinion for a novel food ingredient produced through gas fermentation. It follows a scientific risk assessment for Solein from EFSA, with the regulator concluding Solein is safe for use as a protein ingredient in selected food categories. The company has already launched products containing Solein in other markets where it has received approval, including ice cream and dessert products in Singapore, in collaboration with Ajinomoto, and a protein powder in the US, in collaboration with the Planta nutrition brand. Solein is developed through the fermentation of a microbe found in Finnish nature, using carbon dioxide and electricity. The resulting novel ingredient has been marketed by the brand as ‘protein from thin air,’ described as being uniquely versatile across numerous food applications and offering a nutritionally rich profile that can bring a source of iron, fibre and B vitamins alongside protein. Solar Foods has also highlighted the ingredient’s ability to provide predictable supply and consistent quality, as its fermentation production method allows it to be developed independently of agricultural land, weather and climate conditions. This comes at a time when traditional protein supply chains, such as for whey and other dairy proteins, have been subject to supply shortages and price volatility. The positive scientific opinion moves the company’s novel food application to the final stage of the EU approval process. The European Commission will draft an implementing act and present it to the Committee, consisting of EU member state representatives, for voting. Solar Foods said it expects the remaining EU authorisation process to take around 7-9 months, based on recent novel food approval timelines. The company highlighted the significant commercial opportunity presented by Europe alongside the US, with the total addressable market for Solein in the EU approximately €7 billion and in the US, €11 billion by 2030. “Europe is one of the world’s largest and most attractive protein markets, and a strategically important market for Solein,” said Rami Jokela, CEO of Solar Foods. “We are already in discussions with major international food companies, and the positive EFSA opinion enables us to advance these discussions towards commercial agreements”. Through enabling Solar Foods to advance European offtake negotiations, the positive opinion will also enable the company to advance financing and preparations for the final investment decision for its Factory 02 manufacturing site. “After years of proving the technology, product and production process, our focus is increasingly on commercial execution and scaling the business,” Jokela added.
- Grubby collaborates with gut health expert and Zoe co-founder Tim Spector on latest recipes
UK plant-based recipe kit brand Grubby has teamed up with microbiome scientist and Zoe co-founder Tim Spector on a series of new gut-friendly dishes for home cooks. The dishes are from Spector’s new cookbook, Good Mood Food, developed to support mood, energy levels and long-term brain health. The partnership follows Grubby’s previous collaboration with Zoe’s head nutritionist Federica Amati. Zoe is a UK-based personalised nutrition company with a focus on microbiome science and metabolic health. The company has also recently expanded into the consumer products category, launching a fibre-rich snack bar into retail. The limited-edition Grubby menu collaboration features five recipes from Spector’s book, tailored for scratch-cooking at home: Miso Tofu Kimchi Tray Bake, Mushroom and Hispi Cabbage Pappardelle, Mushroom and Lentil Bolognese, Zingy Chick’n Casserole, and Fragrant Thai Green Curry. As with all of Grubby’s offerings, each kit arrives with pre-portioned whole-food ingredients and recipe cards. Martin Holden-White, founder of Grubby, said: “We’re all about making delicious meals, super convenient and simple to cook, and bringing these gut friendly, plant-rich recipes to life has been a real pleasure”. “Tim’s new book proves just how transformative plant diversity is for physical and mental health, and we’re proud to be the only place where people can cook these delicious dishes from scratch with everything delivered straight to their door.”












